EULAR Study Group on Registers and Observational Drug Studies (RODS)

Slides:

Advertisements

Similar presentations

Biologics for Children with Rheumatic Diseases An Introduction.

Advertisements

Pragmatic use of data for research, audit and revalidation Will Dixon Health Informatics Unit 10 th anniversary Royal College of Physicians, 15 th Sept.

OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.

Rituximab for the Treatment of Rheumatoid Arthritis

BAD Biologic Interventions Register (BADBIR ) An update November 2010.

Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.

Consultant Rheumatologist

Kitty Jager & Anneke Kramer, Jane Tizard, Enrico Verrina, Vianda Stel and Karlijn van Stralen On behalf of he ERA-EDTA and ESPN Registry Committees ERA-EDTA.

The Cancer Registry of Norway Jan F Nygård Head of the IT-department.

Musculoskeletal Pain Clinical Study Group Report on Podiatry Consensus Meeting Prof. Jim Woodburn School of Health & Social Care. Glasgow Caledonian University,

Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis The Annals of the.

Rheumatic and Musculoskeletal Diseases Study Group

Professor, Rheumatology Division, Ankara University Medical Faculty

The Management of Comorbid Conditions in Patients with Rheumatoid Arthritis Collaborative Care.

EULAR Study Group on Systemic Lupus Erythematosus (SLE) Dimitrios T

EULAR nurses study group for REsearch and STrategy (REST)

Risk Factors for Rheumatoid Arthritis

Musculoskeletal Health in Europe

Nat. Rev. Rheumatol. doi: /nrrheum

Clinical Research Methodology Course

Risk Factors for Rheumatoid Arthritis

EULAR nurses study group for REsearch and STrategy (REST)

Summary of TB cases across indications and trial periods

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Nat. Rev. Rheumatol. doi: /nrrheum

EULAR Study Group: Public Health in Rheumatic and Musculoskeletal Diseases Suzanne M.M. Verstappen on behalf of the Study Group Who we are: What we.

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Case Collection in RA: Highlights of an Interactive Workshop

EULAR Physical Activity & Exercise Therapy Study Group

(A) EULAR response based on DAS28 (ESR, otherwise CRP) and (B) Boolean remission, at 6 months in patients treated with abatacept as a first-line biologic.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

EULAR Physical Activity & Exercise Therapy Study Group

EULAR Study Group on patient education

EULAR Study group on patient education

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

EULAR Study Group on Registers and Observational Drug Studies

EULAR Psychology Study Group

Percentage of patients achieving EULAR response

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Registri sul tumore della prostata: esperienze internazionali

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

BioCapital Europe 2019, Amsterdam

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

EULAR-defined characteristics describing arthralgia at risk for RA

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Clinical response in patients with early and established RA at month 24. *p

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

The Study Group aims to:

EULAR Study group on patient education

EULAR Study Group on SLE

EULAR Study Group: Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatology Aim of the study group To understand the required clinical and economic.

Satisfaction with control of RA

EULAR Study Group for Collaborative Research

EULAR Study Group for Risk Factors for Rheumatoid Arthritis

European League Against Rheumatism points to consider for the use of big data in rheumatic and musculoskeletal diseases.

All registries/studies are anti-TNF focused, excepting ORA (abatacept), AIR (rituximab), and RABBIT (anti-TNFs and anakinra). AIR = Autoimmunity and Rituximab;

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

EULAR Synovitis Study Group: ESSG

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Sera metabolite profiles of patients with RA discriminate rituximab responders and non-responders. Sera metabolite profiles of patients with RA discriminate.

Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with RA from five RA registries and one RA.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

EULAR Study Group on Registers and Observational Drug Studies (RODS) What we do References- Courses - Publications Aim of the Study Group To create a platform for methodological, logistic, and scientific collaboration across European Rheumatology drug registers in order to maximise the potential use of the data collected within each register, to maximise the quality of the scientific outputs within and across registers, and to maximise the exchange of experiences across registries Organisation of the EULAR RODS meetings (1). Next meeting is planed on 30th November to 1st of December 2018 in Amsterdam Completion of a collaborative study on melanomas in relation to biological anti-rheumatic therapies, a joint effort across 11 European biologics registers (2). Completion of a collaborative study on lymphoma characteristics in relation to different RA therapies (3). EULAR Task Force on RA data harmonisation for registries (4). EULAR Task Force on GCA data harmonisation and core set of variable for registries (5) https://www.eular.org/epidemiology_regis ters_observational_drug_studies_meetin g.cfm Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers Annals of the Rheumatic Diseases 2017;76:386-391 Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the Rheumatic Diseases 2017;76:2025-2030. Radner H, Chatzidionysiou K, Nikiphorou E, et al. 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Annals of the Rheumatic Diseases Published Online First: 04 January 2018 Who we are Rheumatologists, health professionals, statisticians, epidemiologist interested in clinical research using observational data Background Studies on rare exposures, uncommon outcomes, or personalised medicine require large samples that are increasingly difficult to obtain for any single investigator or registry EULAR has supported collaborations among national registers via several specific task forces to streamline collaborative research among registries Point of contact: Axel Finckh : Axel.Finckh@hcuge.ch Johan Askling: johan.askling@ki.se